Stable COPD Patients Clinical Trial
Official title:
Effect of Vitamin D3 on Lung Function and Exercise Tolerance in D3 Deficient COPD Patients
Background: Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and
mortality throughout the world which is a preventable as well as treatable disease. It has
some important extra pulmonary effects which may contribute to the magnitude of the severity
of this disease. Standard therapeutic treatment alone does not optimize its remedy. Vitamin
D3 has been found to improve the physical efficiency of patients with various morbid
disorders, including respiratory ailments. Hypothesis:Vitamin D3 administration in stable
patients with moderate COPD improves lung function variables along with exercise tolerance.
Objectives: To evaluate the effects of Vitamin D3 on lung functions and exercise tolerance in
patients with stable moderate COPD. Methods: For this, a prospective interventional
randomized double blinded study will be carried out on 46 vitamin D3 deficient (serum 25
dihidroxycholecalceferol less than 30 ng/ml), male, stable (diagnosed patient, who has not
experienced any acute exacerbation , hospitalizations , urgent care visits, or changes in
routine medication within 4 weeks prior to study), moderate (post bronchodilator
FEV1/FVC<0.70 of predicted value and FEV1=50 to 79% of predicted value) COPD patients (age
≥40 years), who will be selected from the Out Patient Department (OPD) of the National
Institute of Diseases of Chest and Hospital (NIDCH) and will be grouped as A (control) and B
(study) groups, respectively. All the patients will be again designated as A0, A90 (without
D3) and B0, B90 (with D3) for before and after 90 days of follow up. All the participants
will be matched in terms of duration of COPD, history of smoking, occupation and
socioeconomic status. Along with the standard pharmacological treatment of COPD, the patients
of the 'Study group' will be prescribed for 80000 IU of oral vitamin D3 pre week for
consecutive 3 months. Along with this, all patients both the groups will be advised to
continue ad lib (according to their own choice) diet. At the very 1st day of the study, the
lung functions will be assessed by measuring Forced vital capacity (FVC), Forced expiratory
volume in one second (FEV1), Forced expiratory ratio (FEV1/FVC%), Peak expiratory flow rate
(PEFR) and Forced mid expiratory flow of FVC(FEF25-75%), with a portable digital spirometer.
In addition, exercise tolerance will be assessed by change in 6 Minute Walk Distance (6MWD)
in 6 Minute Walk Test (6MWT). Changes in peripheral capillary oxygen saturation (SpO2) by
Pulse Oximeter and degree of dyspnoea by Modified Borg Scale (MBS) will also be measured both
before and after 6MWT to evaluate their change in both the groups. All these variables will
be measured again among same 46 patient after 90 days standard pharmacological treatment of
COPD with D3 intervention (B group) and also without D3 intervention (A group). For
statistical analysis, Chi-square test, independent sample 't' test between two groups, paired
Student's 't' test within two specific measurements of different durations of each group
,will be done. In the interpretation of results, ≤0.05 level of probability (p) will be
accepted as significant.
1. Introduction:
Chronic Obstructive Pulmonary Disease (COPD) is one of the major causes of chronic
morbidity and mortality throughout the world . Many people suffer from the disease for
years and die too early from its complications. COPD is the fourth leading cause of
death in adults of United States and also projected to be the third by 2020 .Though it
is a preventable and treatable disease, once developed the disease along with its
comorbidities cannot be cured. But its progression and morbidity can be reduced.
The airflow obstruction in this disease is generally persistent as well as progressive
.It has two clinical phases (stable phase and exacerbation phase), both of which are
associated with inflammation .Independent risk factors for COPD are male gender,
advanced age, low socioeconomic status, occupational exposure and cigarette smoking
(both active and passive) ,reactivity of airways, occupational factors and air pollution
.
Vitamin D is a steroid important in bone mineralization and calcium homeostasis. The
prevalence of vitamin D deficiency has been increasing in the general population in
recent decades. The majority of circulating 25-hydroxyvitamin D [25(OH)D] is derived
from sun exposure with a limited dietary contribution. The increased prevalence of
vitamin D deficiency is attributed to sun avoidance, indoor lifestyle, use of sunscreen,
and decreased intake of vitamin D-containing foods .Because vitamin D is sequestered in
adipose tissue, the increasing prevalence of obesity also increases the prevalence of
vitamin D deficiency .
Recently, research has found that vitamin D may play a role in multiple chronic diseases
such as cancer, autoimmune diseases, infections, and cardiovascular disorders . Vitamin
D may also have a role in several diseases involving the respiratory system. Recently
some researchers reported that a significant proportion of young COPD patients may have
insufficient (20 to 29 ng/ml) serum 25-OHD . Moreover, higher serum vitamin D
concentrations, assessed by [25(OH)D], have been associated with better lung function as
measured by FEV1 in a large cross-sectional study of the U.S. population . Although the
precise connection between vitamin D status and lung function is not clear at this
point, it is postulated that vitamin D may improve lung function through its action on
regulating inflammation ,inducing antimicrobial peptides , and/or its action on muscles
.
It has also been suggested that, patients with COPD have a high prevalence of vitamin D
deficiency, ranging from approximately 30% in mild COPD to over 75% in severe COPD.
Particularly for COPD, vitamin D deficiency may enhance chronic airway and systemic
inflammation, reduce bacterial clearance, and increase the risk for infectious
exacerbations at the same time .
To provide a quick, acceptable as well as repeatable and reproducible lung function data
spirometry is a safe and practical procedure .The ventilatory functions of the lung such
as, forced vital capacity (FVC), forced expiratory volume in 1st second (FEV1), FEV1/FVC
ratio (FEV1/FVC %), forced mid expiratory flow rate between 25% and 75% of FVC
(FEF25-75%) and peak expiratory flow rate (PEFR), can be assessed by spirometry. The
indices derived from this forced exhaled maneuver have become the most accurate and
reliable way of supporting a diagnosis of COPD . This test should be undertaken in all
patients who may have COPD. It is needed to make a confident diagnosis as well as to
exclude other diagnoses that may present with similar symptoms. Although spirometry does
not fully capture the impact of COPD on a patient's health, it remains the gold standard
for diagnosing the disease and monitoring its progression. It is the best standardized
most reproducible and most objective measurement of airflow limitation available .
In addition, oxygen saturation is an indicator of the percentage of hemoglobin saturated
with oxygen at the time of the measurement. Peripheral capillary oxygen saturation
values obtained from pulse oximetry (SpO2) is one part of a complete assessment of the
patient's oxygenation status. Normal oxygen saturation values are 97% to 99% in the
healthy individual and of 95% is clinically accepted in a patient with a normal
hemoglobin level . This value may vary with the amount of oxygen utilization by the
tissues. For example, in some patients, there is a difference in SpO2 values at rest
compared with those during activity, such as ambulation or positioning. However it does
not reflect the patient's ability to ventilate .
Moreover, dyspnea is one of the most significant symptoms occurring during the
progression of COPD and results from pulmonary hyperinflation, weakness of inspiratory
muscles, increased ventilation, voluntary hyperventilation, increased respiratory work
load and impaired function of the inspiratory muscles . The evaluation of dyspnea is
very important in any chronic respiratory ailment. The effort dyspnea determined at the
end of exercise is accepted as the best indicator of dyspnea .There are several scales
are available to evaluate dyspnea. Though the interpretation of dyspnea scales depends
solely on the statements of the patients, but Modified Borg Scale (MBS) is known to be
simple and partially objective, have usually been used to evaluate effort dyspnea in
clinical practice .
Respiratory disease often presents with limited activity level and exercise capacity and
reduced exercise tolerance is a hallmark of patients with COPD . In 1963, Balke
developed a simple test to evaluate the functional capacity by measuring the distance
walked during a period of time. Walk test are typically administered as a means of
evaluating functional status, monitoring treatment effectiveness and establishing
prognosis. The 6 minutes walk test (6 MWT) is a practical simple test that requires a 30
meter hallway but no exercise equipment or advance training for the observer. The test
measures the distance that a person can quickly walk on a flat, hard surface in a period
of 6 minutes. The self paced 6 MWT assesses the submaximal level of functional capacity.
However, because most activities of daily living are performed at submaximal levels of
exertion, the 6 minutes walk distance (6 MWD) may better reflect the functional exercise
level for daily physical activities.
2. Rationale:
Standard therapeutic treatment schedule has a limited role in improving the physical
capacity in COPD patients .Various supplementations and extra-therapeutic measures have
been tried to improve the functional capacity of the COPD patients . Vitamin D3
supplementation is one of them. The principal goals of adding vitamin D3 in the
treatment schedule of these patients are to reduce symptoms and exacerbations, to
improve quality of life and to increase physical and emotional participation in everyday
activities which may not be adequately addressed by standard pharmacological regime
alone for COPD .Recently, a number of studies have shown an association between vitamin
D deficiency and severity of COPD . In addition in a prospective study, FEV1 was measured
in patients with severe and very severe COPD both before and after vitamin D3
supplementation and significant improvement was found .On the other hand, one recent
study reported no significant improvement in FVC, FEV1 and FEV1/FVC% in Vitamin D3
insufficient COPD patients after vitamin D3 administration as compared to that of the
control group .
However the volume of information regarding the effect of vitamin D3 administration in
COPD patients is not enough for reaching any final conclusion. Moreover, with the best
of our knowledge no study have been conducted to observe the effects of this fat soluble
vitamin on the spirometric lung function status, oxygen saturation and exercise
tolerance in vitamin D3 insufficient, stable patients with moderate COPD.
Therefore, on the basis of this background the present study has been designed to
evaluate the effects of Vitamin D3 on the spirometric lung function status, peripheral
capillary oxygen saturation and exercise tolerance in D3 insuffucient, male patients
with stable moderate COPD. This study will draw attention of the physicians about the
beneficial effects of the vitamin D3 on both pulmonary and extrapulmonary complications
in COPD patients.
Research Question:
Does vitamin D3 has any effect on lung function and exercise tolerance in stable COPD
patients?
Hypothesis:
Vitamin D3 administration in stable patients with moderate COPD improves lung function
variables along with exercise tolerance.
Objectives:
General Objective To evaluate the effects of vitamin D3 administration on lung functions
and exercise tolerance in vitamin D3 insufficient male patients with stable moderate
COPD.
Specific Objectives
- To measure the FVC, FEV1, FEV1/FVC%, PEFR and FEF25-75% of vitamin D3 insufficient
male patients with stable moderate COPD, in order to assess their lung function
status.
- To measure the SpO2 at rest, in order to assess the basal oxygenation status in
this group of patients.
- To determine level of dyspnea at rest, in order to assess the basal breathlessness
level in the same group of patients
- To measure the 6MWD of all the patients, in order to assess their functional
exercise capacity.
- To measure both the SpO2 and level of dyspnea again after 6MWT, for the assessment
of their exercise tolerance.
- To measure all these variables after 90 days standard pharmacological treatment
with vitamin D3 and also without vitamin D3 in stable COPD patients.
- To compare the results of baseline and endline.
Methodology:
TYPE OF STUDY : Prospective interventional randomized double blinded study PLACE OF
STUDY : Department of Physiology, Bangabandhu Sheikh Mujib Medical University (BSMMU),
Shahbagh, Dhaka STUDY PERIOD : March 2017 to February 2018 STUDY POPULATION : Stable,
moderate COPD patients with vitamin D3 insufficiency.
SAMPLE SIZE : 46 SAMPLING : Simple random sampling . According to the selection criteria
total 46 COPD patients suitable for the aims and objectives of the study, will be
enrolled. 46 patients of COPD will be selected by clinician in OPD.
GROUPING OF THE SUBJECTS :
Group A (Control group) : 23 D3 insufficient COPD patients without D3 administration A0
: On day 0 A90 : On day 90 Group B (Study group) : 43 (forty three) D3 insufficient COPD
patients with D3 administration B0 : On day 0 B90 : On day 90
Sample size calculation:
Using the following statistical formula n = (Zα+Zβ) 2 X (σ12+σ22) (μ1-μ2)2
Here, Using the following statistical formula n = [(Zα+Zβ)2 X (σ12+σ22)] / (μ1-μ2)2 Mean
of control, μ1 = 47.1 Mean of study group, μ2 = 67.4 SD of control, σ1 = 26.9 SD of
study group, σ2 = 27.5 (Martineau et al. 2015) Type I Error, Zα = 1.96 Type II Error, Zβ
= 1.64 (Kirkwood and Sterne 2003) (Kirkwood and Sterne 2003)
Therefore, n = [(Zα+Zβ)2 X (σ12+σ22)] / (μ1-μ2)2
- [(1.96+1.64)2 X (26.92 +27.52) / (47.1-67.4)2
- [12.96 X (756.25+723.61)] / (20.3) 2 = 19178.98 / 412.09 = 46.54 = 47
Subject Selection:
After selection of subject the researcher will sit for an interview with the subject.
The researcher will at first introduce himself mentioning his institutional affiliation,
conflict of interest and will supply address, contact telephone number and information
about sponsorship. After that the subject will be thoroughly informed about the
objectives and outcome of the study. Brief explanation of the procedure will be given to
them. The subject will also be assured if any problem arises during the test; it will be
taken care of. The result of the test will be sent to him free of charge and if any
abnormality is detected, then appropriate management will be given to him, if possible
or will be referred to specific treatment facility as appropriate. He will be encouraged
for voluntary participation in a cordial and friendly attitude and will be allowed
freedom to withdraw from the study whenever he likes even after participation. They will
be informed about the method of confidentiality of their identification. Their identity
will be recorded only in questionnaire which will be kept in safe custody with the
researcher. It will not enter in the computer and will not go in any publication. No
personal identification will be used in data analysis, report writing or publication.
They will also be assured that interview time will minimum for maintaining their
comfort, some questions will be asked about the personal, family and medical history
without any private enquiry. The conflict of interest will be told to him if there is
any. After he has understood these entire procedure, if he agrees to participate, then a
willingly given informed written consent will be taken from him.
There is no possibility of any physical, social or mental risk of the respondent. A
pretested questionnaire will be filled up by the research assistant.
All gathered information will be kept secret and only will be used for medical research
and analysis.
SITE OF SAMPLE COLLECTION:
All the patients will be collected from the Out Patient Department (OPD) of National
Institute of Diseases of Chest and Hospital
STUDY PROCEDURE:
On the first day of enrollment, the objectives, nature, purpose and potential risk of
all the procedures used for the study will be explained in detail to each subject, with
a cordial attitude giving emphasis on the benefits he might obtain from this study. He
will be encouraged for voluntary participation and will be allowed to withdraw himself
from the study even after participation, whenever he felt uneasy. If he agreed to be
enrolled in the study, an informed written consent will be taken in a prescribed form .
Detailed family history, medical history and thorough physical examination of each
patient will be done and all the information will be recorded in a standard data sheet .
Then all the patients will be requested to attend the Department of Physiology at 9 am
(about 1 and 1/2 hours after his breakfast) on the day of biochemical and spirometric
examination.
On the examination day, 5 ml of venous blood will be collected and taken to the
Hematology laboratory as soon as possible for the estimation of serum
25-hydroxycholecalceferol, serum glucose 2 hours after breakfast and serum creatinine.
After that his height and weight will be measured and the spirometric lung function test
will be done by using a portable spirometer. After getting all the biochemical and
spirometric reports the final selection will be done, according to the inclusion and
exclusion criteria.
Subsequently, all the eligible patients will be randomly assigned to either 'Control' or
'Study' groups and will be thoroughly informed about the objectives and detailed study
procedure, once again. Then the patients will be examined for the baseline value of all
the study variables in Day 1.
Again after 90 days the study variables will be collected from same 86 patients.
Vitamin D3
Ingredient
- Cholecalciferol (40,000IU)
- Microcrystalline Cellulose (58.1 gm)
- Butylated Hydroxy Toluene ( 0.2mg)
- Magnesium Stearate (3mg)
- Gelatin Capsule Shell (1mg)
Dose : 80,000 IU/wk
Route : Oral
Placebo : Courtesy of Beximco Pharmaceuticals Limited
- Bangladesh Ingredient : • Microcrystalline Cellulose (303.8gm)
- Butylated Hydroxy Toluene (0.2mg)
- Magnesium Stearate (3mg)
- Gelatin Capsule Shell (1mg)
STUDY VARIABLES:
1. Spirometric variables
• FVC (L) : Forced Vital Capacity
• FEV1 (L) : Forced Expiratory Volume in 1st second
- FEV1/FVC Ratio (%) : Forced Expiratory Ratio
- PEFR (L/min) : Peak Expiratory Flow Rate
- FEF 25-75 (L/S) : Forced Expiratory Flow in the middle of FVC
2. Oxygenation variables
• Resting SpO2 (%) : Resting Peripheral Capillary Oxygen saturation
3. Exercise tolerance variables • 6MWD (meter) : Six Minute Walk Distance • Level of
Dyspnea : Modified Borg Scale
4. Hematological variables • 25(OH)D (ng/ml) : 25-hydroxycholecalceferol • PTH (pmol/l) :
Parathyroid hormone • Ca2+ (mg/ml) : Ionic calcium • PO43- (mg/ml)
- Ionic phosphate
- AP (U/L) : Alkaline Phosphatase
Subsequently a standard therapeutic treatment will be prescribed to all the selected stable
moderate COPD patients. In addition, the patients of the 'Study group' will be prescribed for
80000 IU of oral vitamin D3 per week for consecutive 90 days . Along with this, all the
patients of both the groups will be advised to continue ad lib (according to their own
choice) diet.
Proper education will be given about drug , method of taking medication and medication
plan.Afterwards,a good rapport will be built up to take time to time follow up over telephone
and visiting patient's place .Schedule appointment ,hotline and follow up will be maintained
properly. They will be requested to attend the Department of Physiology again on the 90th
day, to have the assessment of all the above-mentioned study variables Any patient, who
failed to follow the study procedure exactly during study period, will be dropped and a new
one will be included to fulfill the desired total sample number.Thats why extended sample
should be taken to fulfill the total sample number.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02789540 -
Latin American Study of 24-hs Symptoms in Chronic Obstructive Pulmonary Disease (COPD) Patients; LASSYC Study
|
N/A |